Trial Profile

A multi-center, double-blind, randomized, placebo-controlled, Phase Ib First-in-Human and Proof-of-Concept study to evaluate the safety, tolerability, and efficacy of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis (CPP)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ZL-1102 (Primary)
Indications Plaque psoriasis
Focus Adverse reactions; First in man; Pharmacodynamics; Proof of concept; Therapeutic Use
Sponsors ZAI Lab

22 Dec 2021 Protocol was amended to include efficacy and pharmacodynamic endpoints.
22 Dec 2021 Status changed from active, no longer recruiting to completed.
21 Oct 2021 Status changed from recruiting to active, no longer recruiting according to Crescendo Biologics Ltd media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com